Antithrombotic activity of argatroban in experimental thrombosis in the rabbit

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 3, 1996, Pages 233-241

  Berry, Christopher N ^a   Girard, Denise ^a   Girardot, Christine ^a   Lochot, Sylvette ^a   Lunven, Catherine ^a   Visconte, Catherine ^a  

^a SANOFI   (France)

Author keywords

Animal models; Antithrombin; Argatroban; Heparin; Thrombosis

Indexed keywords

ANTITHROMBIN III; ARGATROBAN; HEPARIN CALCIUM; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; DOSE RESPONSE; FEMORAL ARTERY FLOW; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; THROMBIN TIME; THROMBOGENESIS; THROMBOSIS;

EID: 0030011627     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999013     Document Type: Article

References (30)

1. Okamoto S, A Hijikata, R Kikumoto, S Tonomara, H Hara, K Ninomiya, A Maruyama, M Sugano, Y Tamao: Potent inhibition of thrombin by the newly synthesized arginine derivative no. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101:440-446, 1981.
2. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2- piperidinecarboxylic acid. Biochemistry 23:85-90, 1984.
3. Tapparelli C, R Metternich, C Ehrhardt, M Zurini, G Claeson, MF Scully, SR Stone: In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 268:4724-4741, 1993.
4. Bush LR: Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 9:247-263, 1991.
5. Kumada T, Y Abiko: Comparative study of heparin and a synthetic thrombin inhibitor no 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 24:285-298, 1981.
6. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40:498-530, 1990.
7. Iida S, T Komatsu, T Hirano, Y Fujimura, H Nakai, K Kitazawa, Y Kumagai, T Sato, K Hayashi, K Inokuchi: Pharmacokinetic studies of argatroban (MD-805) in dogs and rabbits. Blood or plasma level profile, metabolism, excretion and accumulation after single or consecutive intravenous administration of argatroban. Oyo Yakuri (Pharmacometrics) 32:1171-1177, 1986.
8. Clarke RJ, G Mayo, GA Fitzgerald, DJ Fitzgerald: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 83:1510-1518, 1991.
9. Berry CN, D Girard, S Lochot, C Lecoffre: Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transeetion bleeding time. Br J Pharmacol 113:1209-1214, 1994.
10. Wessler S, SM Reimer, MC Sheps: Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 14:943-946, 1959.
11. Peters RF, CM Lees, KA Mitchell, MF Tweed, MD Talbot, RB Wallis: The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin (CGP 39393), heparin, and iloprost. Thromb Haemostas 65:268-274, 1991.
12. Hladovec J: Experimental thrombosis in rats with continuous registration. Thromb Haemostas 26:407-410, 1971.
13. Morishita K, M Wada, T Kumada, T Tanaka, M Tomikawa, M Iwamoto: Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thromb Res 63:373-384, 1991.
14. Imura Y, J-M Stassen, D Collen: Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmaeol Exp Ther 261:895-898, 1992.
15. Freund M, J-P Cazenave, M Courtney, E Degryse, C Roitsch, A Bernat, D Delebassee, G Defreyn, J-P Maffrand: Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemostas 63:187-192, 1990.
16. Gray E, J Watton, S Cesmeli, TW Barrowcliffe, DP Thomas: Experimental studies on a recombinant hirudin CGP 39393. Thromb Haemostas 65:355-391, 1991.
17. Schumacher WA, TE Steinbacher, CE Heran, SM Seiler, NM Michel, ML Ogletree: Comparison of thrombin active site and exosite inhibitors and heparin in experiments of arterial and venous thrombosis and bleeding. J Pharmaeol Exp Ther 267: 1237-1242, 1993.
18. Fumagalli G, E Angelaccio, N Lombardo, E Clementi: Morphometric and ultrastructural study of experimental venous thrombosis. Haemostasis 17:361-370, 1987.
19. Jang I-K, HK Gold, AA Ziskind, RC Leinbach, JT Fallon, D Collen: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81:219-225, 1990.
20. Hara H, Y Tamao, R Kikumoto: Effect of argatroban (MD-805) on platelet function. Jpn Pharmaeol Ther 14 (suppl 5):13-19, 1986.
21. Tamao Y, T Yamamoto, R Kikumoto, H Hara, J Itoh, T Hirata, K Mineo, S Okamoto: Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromh Haemostas 56:28-34, 1986.
22. Talbot MD, JA Ambler, KD Butler, CM Lees, KA Mitchell, RF Peters, MF Tweed, RB Wallis: The effects of recombinant desulphatohirudin on arterial thrombosis in rats. Haemostasis 21 (suppl 1):73-79, 1991.
23. Hanson SR, LA Harker: Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 85:3184-3188, 1988.
24. Heras M, JH Chesebro, M Webster, JS Mruk, DE Grill, WJ Penny, EJW Bowie, I Badimon, V Fuster: Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 82:1476-1484, 1990.
25. 4) purification and characterization by affinity chromatography. J Biol Chem 251: 324-328, 1976.
26. Miletich JP, CM Jackson, PW Majerus: Properties of the factor Xa binding site on human platelets. J Biol Chem 253:6908-6916, 1978.
27. Mirshahi M, J Soria, C Soria, R Faivre, H Lu, M Courtney, C Roitsch, D Tripier, JP Caen: Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 74:1025-1030, 1989.
28. Weitz JI, M Hudoba, D Masel, J Maraganore, J Hirsh: Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 86:385-391, 1990.
29. Berry CN, C Girardot, C Lecoffre, C Lunven: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemostas 72:381-386, 1994.
30. Lunven C, C Gauffeny, C Lecoffre, D O'Brien, NO Roome, CN Berry: Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemostas 75:154-160, 1996.